{
    "nctId": "NCT06307457",
    "briefTitle": "A Study of HR+/HER2- Metastatic Breast Cancer Patients Treated With Palbociclib Together With an Aromatase Inhibitor From 2017 to 2023 in Denmark.",
    "officialTitle": "Impact of Age and Comorbidities on Treatment Outcomes of First-line Treatment With Palbociclib in Combination With an Aromatase Inhibitor (AI) in Patients Diagnosed With HR+/HER2 - Metastatic Breast Cancer - Danish Non-Interventional Study",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 1,
    "primaryOutcomeMeasure": "Progression-free Survival (PFS) of all mBC patients receiving palbociclib in combination with AI as first-line treatment",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Patients with breast cancer (ICD-10: C50)\n* A diagnosis of HR+/HER2- locally advanced or metastatic breast cancer\n* Endocrine sensitive, endocrine resistant, or de novo mBC patient\n* Inclusion date: Date of relapse/stage IV disease/progression leading to initiation of palbociclib+AI\n\nExclusion Criteria:\n\n* There are no exclusion criteria for this study",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}